Welcome to our dedicated page for Northwest Bio SEC filings (Ticker: NWBO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Northwest Biotherapeutics, Inc. (NWBO) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a reporting issuer whose common stock trades on the OTCQB. Through these filings, investors can review how Northwest Biotherapeutics describes its business of developing DCVax dendritic cell-based immunotherapies for solid tumor cancers, along with details on governance, financing, and capital structure.
Key documents include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company discusses its DCVax-L and DCVax-Direct programs, clinical trial status, manufacturing initiatives such as the Flaskworks system and the Sawston, UK facility, and risk factors relevant to its operations. These reports also provide information on research collaborations, in-licensed dendritic cell technology portfolios, and the acquisition of Advent BioServices Ltd.
Frequent current reports on Form 8-K highlight material events such as convertible note financings, commercial loan agreements, filing of shelf registration statements on Form S-3, settlement of litigation related to option awards, and the closing of the Advent acquisition. 8-K filings also document shareholder meeting outcomes, including votes on director elections, auditor ratification, increases in authorized common stock, and advisory votes on executive compensation.
Proxy statements on Schedule 14A (DEF 14A) provide further detail on corporate governance, board composition, compensation policies, and proposals presented to stockholders at annual meetings. Amendments to the certificate of incorporation, such as increases in authorized shares of common stock, are described in both proxy materials and related 8-K filings.
On Stock Titan, these filings are updated as they are released through EDGAR. AI-powered summaries help explain lengthy documents by highlighting core business descriptions, key financing terms, changes in share authorization, and other items that may affect NWBO’s capital structure and strategic flexibility. Users can also review filings related to registration statements and other corporate actions to build a more complete picture of Northwest Biotherapeutics’ regulatory and financial history.
Northwest Biotherapeutics files Post-Effective Amendment converting its October 2025 Form S-3 into a Form S-1 and continues registration of up to 339,842,519 Conversion Shares. The prospectus states 1,606,857,011 shares outstanding as of March 31, 2026 and a pro forma shares outstanding of 1,946,699,530 assuming exercise of all convertible securities. The filing discloses that if the full amount of the Warrants is exercised for cash, the company would receive approximately $25.1 million in gross proceeds. This Post-Effective Amendment notes eligibility changes after filing the 2025 Form 10-K and states that no new securities are being registered by this amendment.
Northwest Biotherapeutics files its 2025 annual report, highlighting progress on its cancer immunotherapy platform and significant ongoing risks. The company’s lead product, DCVax-L for glioblastoma, completed a 331-patient Phase III trial and has a Marketing Authorization Application under review in the U.K. A 40-patient Phase I trial of DCVax-Direct for inoperable tumors is complete, with Phase II planning tied to available resources.
The company expanded sharply, ending 2025 with 105 full-time employees after acquiring UK manufacturer Advent BioServices and focusing production at its Sawston facility. Auditors again issued a going concern opinion, reflecting continued losses and heavy funding needs. Management emphasizes substantial additional capital will be required, continued dilution is likely, and competition in oncology and cell therapy remains intense.
Northwest Biotherapeutics, Inc. completed the acquisition of Advent BioServices Ltd., its UK-based contract development and manufacturing partner for the DCVax® product platform, making Advent a wholly owned subsidiary. The buyer and seller are related parties through the Company’s Chairperson and CEO, Linda Powers.
The consideration includes a purchase price of approximately $1.9 million (£1.4 million) plus payment of about $8.3 million of accounts payable owed to Advent, with certain excluded payables of about $0.7 million retained by the seller. Payments are due in installments over two years, starting three months after closing, with unpaid balances accruing 7.5% annual interest.
At closing, Advent returned 12 million Northwest Biotherapeutics common shares and 5.5 million stock options previously issued for services; the shares were retired to treasury and the options cancelled. The Company also obtained an SEC waiver under Rule 3-13 of Regulation S-X, so it will not provide separate Advent financial statements or pro forma financial information for this acquisition.
Northwest Biotherapeutics notified the SEC it cannot timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company cites complex accounting issues from its acquisition of Advent BioServices, including differences between UK GAAP and US GAAP, and says it will file the 2025 Annual Report as soon as reasonably practicable.
Northwest Biotherapeutics, Inc. has agreed to settle a Delaware Court of Chancery lawsuit over option awards granted to management and directors in 2020. Under the Settlement Agreement, the company’s insurance carriers will pay $2.25 million to the company and 17% of the challenged 2020 stock options will be cancelled, resolving all claims between the parties.
The lead plaintiff intends to ask the court for up to $3,500,000 in attorneys’ fees and expenses, which would be paid separately by the company’s insurers. The agreement and any fee award must be approved at a hearing scheduled for March 16, 2026 at the Leonard L. Williams Justice Center in Wilmington, Delaware.
Northwest Biotherapeutics, Inc. reported the results of its annual stockholder meeting held on December 29, 2025. A quorum was reached, with 1,192,487,345 shares representing 77.4% of the total combined voting power present in person or by proxy.
Stockholders, voting common and preferred shares as a single class, elected Pat Sarma to a new three-year term as a Class II director and ratified Cherry Bekaert LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025.
They also approved an amendment to the Certificate of Incorporation to increase authorized common stock from 1,700,000,000 to 2,600,000,000 shares, and gave advisory approval to the Company’s executive compensation. On December 30, 2025, the Company filed the Certificate of Amendment in Delaware to effect the authorized share increase.
Northwest Biotherapeutics, Inc. is asking stockholders to vote at its December 29, 2025 annual meeting on several key items. Stockholders will elect one Class II director, Pat Sarma, to a three-year term and vote on ratifying Cherry Bekaert LLP as independent auditor for 2025.
A major proposal seeks approval to amend the Certificate of Incorporation to increase authorized common shares from 1.7 billion to 2.6 billion. The company states this is intended to support future capital raising, satisfy existing options, warrants and convertible securities, and potentially provide equity incentives. As of November 14, 2025, there were 1,528,682,082 common shares and 818,142 preferred shares outstanding.
Stockholders will also cast an advisory "say-on-pay" vote on 2024 executive compensation, including total 2024 pay of $1.225 million for CEO Linda Powers and $975,000 for former General Counsel Leslie Goldman. The proxy describes board structure, committee responsibilities, related-party arrangements such as the Advent BioServices contracts ahead of its acquisition, and detailed voting procedures for both record and beneficial holders.
Northwest Biotherapeutics, Inc. is registering 21,739,130 shares of common stock at an offering price of $0.23 per share in connection with a $5,000,000 convertible promissory note financing with YA II PN, Ltd. The company expects net proceeds of approximately $4,750,000 after an original issue discount and expenses. These shares are reserved to repay principal and any accrued amounts on the 12‑month, zero‑interest Note, which carries a 5% original issue discount and is convertible, at the holder’s option, at a small discount to the then‑prevailing market price, subject to monthly conversion limits.
Following this offering, the company estimates it will have 1,562,421,212 shares of common stock outstanding. Net proceeds are earmarked for general corporate purposes, including working capital, capital expenditures such as UK production facilities, research and development, regulatory affairs, clinical trials, and potential technology acquisitions and investments.
Northwest Biotherapeutics, Inc. entered into a $5 million convertible promissory note financing with YA II PN, Ltd. The company plans to use the cash for construction and equipment for its first Grade C manufacturing suite at its Sawston, UK facility, and for ongoing operations. The note has a 12-month term with no payments due until maturity, carries a 5% original issue discount, and does not bear interest.
During the term, the note is convertible at the holder’s option at a small discount to the then prevailing market price. Conversion amounts are generally limited to about one fifth of the $5 million note in any calendar month, unless the conversion price is above $0.29. The agreement includes customary default provisions.